Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Single-blind Prevention

Problem Adaptation Therapy for Mild Cognitive Impairment and Depression

Cognitive Impairment · Depression

Enrolled (actual)
80
Serious AEs
7.5%
Results posted
Aug 2025
Primary outcome: Primary: Change in Global Cognition Assessed by RBANS — 434.66; 435.36; 438.46; 436 Score on a Scale — p=0.9644

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PATH-MCI (Behavioral); Supportive Therapy (Behavioral)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
Weill Medical College of Cornell University
Primary completion
Sep 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Global Cognition Assessed by RBANS
434.66; 435.36; 438.46; 436; 448.57; 449.08 0.9644
SECONDARY
Change in Disability Function Assessed With WHODAS-II
12.08; 10.95; 12.43; 9.47; 10.68; 9.58 0.5454
SECONDARY
Change in Depression Assessed by MADRS
16.62; 16.59; 14.97; 15.03; 13.53; 12.47 0.9813
SECONDARY
Change in Episodic Memory Assessed by Delayed Recall Subscale of RBANS
76.66; 79.59; 77.81; 81.78; 81.89; 87.04 0.5130
SECONDARY
Change in Executive Function Assessed by Trail Making Test
24.94; 25; 24.19; 24.89; 25; 25 0.3248

Summary

The present collaborative R01 study, between Cornell and Johns Hopkins, aims to compare Problem Adaptation Therapy for Mild Cognitively Impaired Older Adults (PATH-MCI) vs. Supportive Therapy for Cognitively Impaired Older Adults (ST-CI) in improving cognitive, affective, and functioning outcomes.

Eligibility Criteria

Inclusion Criteria

  • Amnestic MCI as defined by Albert et al
  • Montgomery Asberg Depression Rating Scale (MADRS) greater than 7 and MADRS total less than 30
  • Participants will be off antidepressants, cholinesterase inhibitors or memantine, or on a stable dosage for at least 12 weeks without any medical recommendation to adjust dosage in next 3 months (during treatment)
  • Clinical Dementia Rating (CDR) = 0.5 at screening
  • Subjects will have capacity to consent

Exclusion Criteria

  • Deemed to have a significant suicide risk as assessed by site PI and clinical team
  • Deemed too unstable medically or neurologically to safely enroll in a research trial
  • Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy. Requiring psychiatric hospitalization at baseline for safety.
  • Current involvement in psychotherapy
  • Lack of English fluency
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03043573). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search